Chinese Pharma Leaders Shine on Global Most Valuable Medical Brands List; Several File IPO Prospectuses

Guangzhou Daily News (All-media Reporter Duanyu Tu) - The "Brand Finance 2024 Global Most Valuable Healthcare Brands Report" was recently released. Johnson & Johnson was once again named the world's most valuable pharmaceutical brand, with its brand value increasing by 5% this year to reach 13.4 billion US dollars. In addition, four Chinese pharmaceutical brands made it into the top 25 of the "Global Most Valuable Pharmaceutical Brands List." Among them, Guangzhou Pharmaceutical Holdings Limited saw a counter-trend growth of 11.3% in brand value, while the brand values of Sinopharm Group, Shanghai Pharmaceuticals, and Yunnan Baiyao experienced varying degrees of decline. Notably, Guangzhou Pharmaceutical Holdings Limited and Shanghai Pharmaceuticals also entered the "Global Most Valuable Medical Device Brands List" for the first time this year.

Brand Finance stated: "The importance of China's pharmaceutical groups and medical service institutions continues to grow. With the continuous advancement of professional technology and significant improvements in industry efficiency, production costs are constantly decreasing. This provides new opportunities for Chinese pharmaceutical companies to gradually become global well-known brands, while also presenting new challenges." It is reported that Chinese pharmaceutical enterprises are actively pursuing international strategic layouts. Guangzhou Pharmaceutical Holdings Limited and its subsidiaries are continuously 'going global,' establishing international headquarters, signing cooperation agreements with Cuba's biopharmaceutical group, and hosting the 2024 China-Vietnam Traditional Chinese Medicine Culture Inheritance and Development Forum in Vietnam. After setting up an international headquarters in Macao, Guangzhou Pharmaceutical Holdings Limited collaborated with Academician Zhong Nanshan's team and Macao University of Science and Technology to promote the industrialization of Baiyunshan Isatidis Radix and Baiyunshan Compound Isatidis Radix research results in Macao, supporting the local pharmaceutical industry's development.